NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), an AI company specializing in clinical trials analytics, has announced a shareholder conference call scheduled for Tuesday, April 15, 2025, from 4:00-4:30pm EST. CEO George Achilleos will lead the discussion on recent developments and growth strategies.
Key highlights include a strategic partnership with Worldwide Clinical Trials, which is integrating NetraAI into various clinical trials, particularly in neuroscience and oncology. The company will discuss its regulatory alignment strategy, focusing on how its explainable AI capabilities support clinical trials and FDA submissions.
The call will also showcase NetraAI's technological differentiation, highlighting its ability to identify subpopulations in small datasets and reduce overfitting. Additionally, NetraMark has extended its agreement with 1502656 B.C for public relations services, with additional compensation of $200,000 CDN for a six-month term.
NetraMark Holdings (OTCQB: AINMF) has announced a global partnership with Worldwide Clinical Trials to enhance clinical trial design using AI technology. The collaboration integrates NetraMark's proprietary NetraAI platform into Worldwide's service offerings, initially focusing on Phase 2 neuroscience and oncology trials, with plans to expand across all therapeutic areas.
The partnership combines Worldwide's three decades of clinical execution excellence and 11 consecutive CRO Leadership Awards with NetraMark's advanced AI solution. The integration aims to optimize clinical trials by identifying hidden patient subpopulations within complex datasets, improving trial efficiency, and delivering regulatory-aligned insights.
Key benefits include accelerated development timelines, refined patient stratification, reduced placebo response variability, and enhanced trial power. The collaboration is expected to enable more informed protocol development, faster decision-making, and improved patient targeting, ultimately leading to fewer required patients per trial, reduced timelines, and lower costs for sponsors.
NetraMark Holdings (OTCQB:AINMF) presented groundbreaking AI research at the ISCTM conference, showcasing advancements in clinical trial analytics for major depressive disorder (MDD) and schizophrenia.
The company's NetraAI Sub-Insight Learning demonstrated significant improvements in MDD clinical trials, achieving:
- 28% increase in model accuracy
- 31% improvement in sensitivity
- 51% increase in specificity
In schizophrenia research, NetraAI identified distinct patient subgroups responding differently to treatments: patients with moderate-severe symptoms responded better to olanzapine, while those with moderate negative symptoms showed improved response to perphenazine.
NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF), a leader in AI-driven clinical trial analytics, will participate in the 2024 Cantech Letter Conference on October 9, 2024, in Toronto. CEO George Achilleos will deliver a corporate presentation at 4:30 pm in Track 2 and conduct 1-on-1 investor meetings.
The presentation will highlight NetraMark's AI technology for optimizing clinical trials, focusing on:
- Identifying subpopulations driving drug response, placebo response, and adverse events
- Informing trial strategies to improve success likelihood
- Proprietary commercial-ready platform
- Collaborations with NIMH, Boston University, and Ontario Brain Institute
- Market entry strategy in CNS and Oncology
- Established client base and sales pipeline
- Favorable financial drivers with 90%+ gross margin
This event aims to strengthen NetraMark's capital market connections and increase investor visibility.
Summary not available.